2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Smoldering Multiple Myeloma
1
Interventions
Specimen Handling
288
Magnetic Resonance Spectroscopy
238
pembrolizumab
228
Carboplatin
187
Cisplatin
153
Biopsy
151
Cyclophosphamide
144
Paclitaxel
133
Nivolumab
123
Gemcitabine
113
Bevacizumab
106
Radiotherapy
96
Dexamethasone
86
Pemetrexed
83
fludarabine
78
Fluorouracil
76
Doxorubicin
76
Docetaxel
76
atezolizumab
73
Radiation
72
Leucovorin
70
Rituximab
68
Oxaliplatin
66
venetoclax
61
durvalumab
61
Prednisone
61
Vincristine
56
Cetuximab
56
Lenalidomide
55
Etoposide
54
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
IPH-2101
×
30 days
×
Clear all
NCT01222286
2026-05-14
KIRMONO
Innate Pharma
Phase 2
Completed
30 enrolled
10 charts